As aberrant NIK activity driving constitutive activation of both canonical and non-canonical NF-κB signaling constitutes a common consequence of most of the genetic aberrations found in a large subset of multiple myeloma and Hodgkin lymphoma patients, pharmacological NIK inhibition represents an attractive therapeutic strategy for the treatment of these tumor entities. The gene discussed is NFKB1; the disease is neoplasm.